In vivo dosimetry (IVD) has been used in brachytherapy (BT) for decades with a number of different detectors and measurement technologies. However, IVD in BT has been subject to certain difficulties and complexities, in particular due to challenges of the high-gradient BT dose distribution and the large range of dose and dose rate. Due to these challenges, the sensitivity and specificity toward error detection has been limited, and IVD has mainly been restricted to detection of gross errors. Given these factors, routine use of IVD is currently limited in many departments. Although the impact of potential errors may be detrimental since treatments are typically administered in large fractions and with high-gradient-dose-distributions, BT is usually delivered without independent verification of the treatment delivery. This Vision 20/20 paper encourages improvements within BT safety by developments of IVD into an effective method of independent treatment verification.
Brachytherapy can deliver high doses to the target while sparing healthy tissues due to its steep dose gradient leading to excellent clinical outcome. Treatment accuracy depends on several manual steps making brachytherapy susceptible to operational mistakes. Currently, treatment delivery verification is not routinely available and has led, in some cases, to systematic errors going unnoticed for years. The brachytherapy community promoted developments in in vivo dosimetry (IVD) through research groups and small companies. Although very few of the systems have been used clinically, it was demonstrated that the likelihood of detecting deviations from the treatment plan increases significantly with time-resolved methods. Time-resolved methods could interrupt a treatment avoiding gross errors which is not possible with time-integrated dosimetry. In addition, lower experimental uncertainties can be achieved by using source-tracking instead of direct dose measurements. However, the detector position in relation to the patient anatomy remains a main source of uncertainty. The next steps towards clinical implementation will require clinical trials and systematic reporting of errors and nearmisses. It is of utmost importance for each IVD system that its sensitivity to different types of errors is well understood, so that end-users can select the most suitable method for their needs. This report aims to formulate requirements for the stakeholders (clinics, vendors, and researchers) to facilitate increased clinical use of IVD in brachytherapy. The report focuses on high dose-rate IVD in brachytherapy providing an overview and outlining the need for further development and research. ☆ During the 1st ESTRO Physics Workshop celebrated in November 2017 in Glasgow, Scotland, a task group was created to stimulate the wider adoption of in vivo dosimetry for radiotherapy. The members of this task group, authors of this report, were selected on the basis of their expertise to contribute relevant input to the area of study and their long-term experience in the clinical implementation of in vivo dosimetry systems.
Many brachytherapy (BT) errors could be detected with real-time in vivo dosimetry technology. Inorganic scintillation detectors (ISDs) have demonstrated promising capabilities for BT, because some ISD materials can generate scintillation signals large enough that (a) the background signal emitted in the fiber-optic cable (stem signal) is insignificant, and (b) small detector volumes can be used to avoid volume averaging effects in steep dose gradients near BT sources. We investigated the characteristics of five ISD materials to identify one that is appropriate for BT. ISDs consisting of a 0.26 to 1.0 mm3 volume of ruby (Al2O3:Cr), a mixture of Y2O3:Eu and YVO4:Eu, ZnSe:O, or CsI:Tl coupled to a fiber-optic cable were irradiated in a water-equivalent phantom using a high-dose-rate 192Ir BT source. Detectors based on plastic scintillators BCF-12 and BCF-60 (0.8 mm3 volume) were used as a reference. Measurements demonstrated that the ruby, Y2O3:Eu+YVO4:Eu, ZnSe:O, and CsI:Tl ISDs emitted scintillation signals that were up to 19, 19, 250, and 880 times greater, respectively, than that of the BCF-12 detector. While the total signals of the plastic scintillation detectors were dominated by the stem signal for source positions 0.5 cm from the fiber-optic cable and >3.5 cm from the scintillator volume, the stem signal for the ruby and Y2O3:Eu+YVO4:Eu ISDs were <1% of the total signal for source positions <3.4 and <4.4 cm from the scintillator, respectively, and <0.7% and <0.5% for the ZnSe:O and CsI:Tl ISDs, respectively, for positions ⩽8.0 cm. In contrast to the other ISDs, the Y2O3:Eu+YVO4:Eu ISD exhibited unstable scintillation and significant afterglow. All ISDs exhibited significant energy dependence, i.e. their dose response to distance-dependent 192Ir energy spectra differed significantly from the absorbed dose in water. Provided that energy dependence is accounted for, ZnSe:O ISDs are promising for use in error detection and patient safety monitoring during BT.
We tested the potential of ruby inorganic scintillation detectors (ISDs) for use in brachytherapy and investigated various unwanted luminescence properties that may compromise their accuracy. The ISDs were composed of a ruby crystal coupled to a poly(methyl methacrylate) fiber-optic cable and a charge-coupled device camera. The ISD also included a long-pass filter that was sandwiched between the ruby crystal and the fiber-optic cable. The long-pass filter prevented the Cerenkov and fluorescence background light (stem signal) induced in the fiber-optic cable from striking the ruby crystal, which generates unwanted photoluminescence rather than the desired radioluminescence. The relative contributions of the radioluminescence signal and the stem signal were quantified by exposing the ruby detectors to a high-dose-rate brachytherapy source. The photoluminescence signal was quantified by irradiating the fiber-optic cable with the detector volume shielded. Other experiments addressed time-dependent luminescence properties and compared the ISDs to commonly used organic scintillator detectors (BCF-12, BCF-60). When the brachytherapy source dwelled 0.5 cm away from the fiber-optic cable, the unwanted photoluminescence was reduced from > 5% to < 1% of the total signal as long as the ISD incorporated the long-pass filter. The stem signal was suppressed with a band-pass filter and was < 3% as long as the source distance from the scintillator was < 7 cm. Some ruby crystals exhibited time-dependent luminescence properties that altered the ruby signal by > 5% within 10 s from the onset of irradiation and after the source had retracted. The ruby-based ISDs generated signals of up to 20 times that of BCF-12-based detectors. The study presents solutions to unwanted luminescence properties of ruby-based ISDs for high-dose-rate brachytherapy. An optic filter should be sandwiched between the ruby crystal and the fiber-optic cable to suppress the photoluminescence. Furthermore, we recommend avoiding ruby crystals that exhibit significant time-dependent luminescence.
Purpose High‐dose rate (HDR) and pulsed‐dose rate (PDR) brachytherapy would benefit from an independent treatment verification system to monitor treatment delivery and to detect errors in real time. This paper characterizes and provides an uncertainty budget for a detector based on a fiber‐coupled high‐Z inorganic scintillator capable of performing time‐resolved in vivo dosimetry during HDR and PDR brachytherapy. Method The detector was composed of a detector probe and an optical reader. The detector probe consisted of either a 0.5 × 0.4 × 0.4 mm3 (HDR) or a 1.0 × 0.4 × 0.4 mm3 (PDR) cuboid ZnSe:O crystal glued onto an optical‐fiber cable. The outer diameter of the detector probes was 1 mm, and fit inside standard brachytherapy catheters. The signal from the detector probe was read out at 20 Hz by a photodiode and a data acquisition device inside the optical reader. In order to construct an uncertainty budget for the detector, six characteristics were determined: (1) temperature dependence of the detector probe, (2) energy dependence as a function of the probe‐to‐source position in 2D (determined with 2 mm resolution using a robotic arm), (3) the signal‐to‐noise ratio (SNR), (4) short‐term stability over 8 h, and (5) long‐term stability of three optical readers and four probes used for in vivo monitoring in HDR and PDR treatments over 21 months (196 treatments and 189 detector calibrations, and (6) dose‐rate dependence. Results The total uncertainty of the detector at a 20 mm probe‐to‐source distance was < 5.1% and < 5.8% for the HDR and PDR versions, respectively. Regarding the above characteristics, (1) the sensitivity of the detector decreased by an average of 1.4%/°C for detector probe temperatures varying from 22 to 37°C; (2) the energy dependence of the detector was nonlinear and depended on both probe‐to‐source distance and the angle between the probe and the brachytherapy source; (3) the median SNRs were 187 and 34 at a 20 mm probe‐to‐source distance for the HDR and PDR versions, respectively (corresponding median source activities of 4.8 and 0.56 Ci, respectively); (4) the detector response varied by 0.6% in 11 identical irradiations over 8 h; (5) the sensitivity of the four detector probes decreased systematically by 0–1.2%/100 Gy of dose delivered to the probes, and random fluctuations of 4.8% in the sensitivity were observed for the three probes used in PDR and 1.9% for the probe used in HDR; and (6) the detector response was linear with dose rate. Conclusion ZnSe:O detectors can be used effectively for in vivo dosimetry and with high accuracy for HDR and PDR brachytherapy applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.